Results 151 to 160 of about 2,758 (199)

Managing transient immune complex reactions in patients with paroxysmal nocturnal hemoglobinuria: clinical observations from the COMMODORE 1 and 2 studies. [PDF]

Ther Adv Hematol
Kulasekararaj AG, Nishimura JI, Röth A, Beveridge L, Buatois S, Buri M, Compagno N, Luder Y, Sreckovic S, Scheinberg P.   +9 more
europepmc   +1 more source

Immunotherapies in neuromyelitis optica: Bayesian network meta-analysis. [PDF]

J Neurol
John N, Lim A, Sunthar SR, Zhang L, Cheng J, Boktor J, Chong V, Ma H, Phan TG.   +8 more
europepmc   +1 more source

Iptacopan in C5 blockade refractory atypical hemolytic uremic syndrome with associated Castleman's disease: case report. [PDF]

BMC Nephrol
Nguyen MD, Ciurea S, Desai S, Kalebasty AR, Tran MH, Gee C, Tadros M, Nguyen VQ, Patel S, Selamet U, Hanna R.   +10 more
europepmc   +1 more source

Ravulizumab for paroxysmal nocturnal haemoglobinuria.

Australian prescriber
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Monitoring Ravulizumab effect on complement assays

Journal of Immunological Methods, 2021
Ravulizumab is a new C5 inhibitor therapeutic monoclonal antibody with a longer half-life than eculizumab. Monitoring complete complement blockade by eculizumab has allowed personalized therapy in specific settings. Similar action is expected with ravulizumab. Ravulizumab has 4 different amino acids from eculizumab, which allow greater affinity for the
Paula M Ladwig
exaly   +3 more sources

Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

NEJM Evidence, 2022
BACKGROUND: Generalized myasthenia gravis (gMG) is a rare, chronic, and debilitating autoimmune disease. Activation of the complement system by autoantibodies against the postsynaptic acetylcholine receptor (AChR) leads to destruction of the postsynaptic membrane and disruption of neuromuscular transmission.
Tuan Vu, Andreas Meisel, Renato Mantegazza   +2 more
exaly   +3 more sources

Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria

Expert Opinion on Biological Therapy, 2020
Introduction: Eculizumab, which is indicated to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), is a life-changing, life-saving therapy that decreases intravascular hemolysis and thrombosis and improves survival. Some eculizumab-treated patients, however, experience breakthrough hemolysis; and overall, the burden of the treatment ...
Jong Wook Lee, Austin G Kulasekararaj
exaly   +3 more sources